在糖尿病足综合征中,用沙芬静脉进行再血管化后的补充基因疗法
Diana Kupczyńska1, Paweł Lubieniecki2, Maciej Antkiewicz1
1Clinical Department of Vascular, General and Transplantation Surgery, Wroclaw Medical University, Borowska Street 213, 50-556 Wroclaw, Poland.
Genes
|October 28, 2023
概括
使用双基因VEGF165/HGF等离子体的基因疗法显示出在重血管化后治疗糖尿病足综合征 (DFS) 的潜力. 虽然愈合率与安慰剂相似,但基因疗法改善了DFS患者的血液流动和氧化.
科学领域:
- 血管外科 血管外科
- 基因治疗 基因治疗
- 糖尿病学 糖尿病学
背景情况:
- 糖尿病足综合征 (DFS) 是糖尿病的严重并发症,通常需要重新血管化.
- 目前对DFS的治疗有局限性,需要探索补充疗法.
- 缺血性,性和性病变是DFS的特征,影响患者的流动性和生活质量.
研究的目的:
- 评估二基斯特龙VEGF165/HGF等离子体基因治疗作为糖尿病足综合征 (DFS) 补充治疗的疗效.
- 评估基因治疗对DFS患者的病变愈合,脚-手臂指数 (ABI) 和截面氧气压 (TcPO2) 的影响.
主要方法:
- 18名患有缺血性DFS病变的患者接受了再血管化,并随机分配到基因疗法 (VEGF165/HGF等离子体) 或安慰剂组.
- 在基线和随访点 (7,30,90,180天) 进行了彩色双重超声波 (CDU),ABI和TcPO2测量.
- 在研究期间,DFS病变的愈合被摄影记录并描述.
主要成果:
- 在基因治疗组中,50%的患者在12周内愈合了DFS病变,平均ABI增加0.25和TCPO2增加30.4mmHg.
- 在对照组中,66.67%的患者在12周内愈合了病变,平均ABI增加0.14和TcPO2增加27.1mmHg.
- 在每个治疗臂中都发生了一次重大截肢,这表明在这方面的结果相似.
结论:
- 双晶体VEGF165/HGF等离子体基因疗法可能为糖尿病足综合征 (DFS) 提供一个有前途的补充治疗选择.
- 虽然直接治愈率与安慰剂相似,但基因疗法在改善血管参数方面显示出潜在的益处.
- 进一步的研究是有必要的,以优化基因疗法协议,以提高DFS治疗结果.
相关概念视频
Varicose Veins II: Diagnostic Studies and Interprofessional Care
14
Varicose veins, or varicosities, develop when the valves in the veins, which control blood flow, weaken or damage. It causes blood to pool and the veins to enlarge. Understanding the clinical manifestations, diagnostic approaches, and management options for varicose veins is crucial for effective treatment and relief.Clinical manifestationsClinical manifestations of varicose veins include a heavy, achy feeling or pain after prolonged standing or sitting. This discomfort can often be relieved by...
14
Peripheral Artery Disease V: Postoperative Nursing Management
12
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
12
Peripheral Artery Disease IV: Nursing Management
11
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
11
Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
192
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
192
Peripheral Artery Disease I: Introduction
9
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs but also impacts other areas, such as the arms, thereby impairing overall circulation and organ function.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty deposits inside the arterial...
9


